Kreftsykdom i øvre urinveier

Dette dokumentet er basert på det profesjonelle dokumentet Uroteliale kreftsvulster i øvre urinveier. Referanselisten for dette dokumentet vises nedenfor.

1. Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av blære og urotelkreft. H-dir: Oslo 2021 www.helsedirektoratet.no 
2. Audenet F, Traxer O, Yates DR, et al. Potential role of photodynamic techniques combined with new generation flexible ureterorenoscopes and molecular markers for the management of urothelial carcinoma of the upper urinary tract. BJU Int 2012; 109: 608-13. PubMed 
3. Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet 2020;395(10232):1268-77. PMID: 32145825 PubMed 
4. Rai BP, Shelley M, Coles B, et al. Surgical management for upper urinary tract transitional cell carcinoma. Cochrane Database Syst Rev 2011:CD007349. Cochrane (DOI) 
5. Mouracade P, Velten M, Gigante M, et al. Factors impacting survival in patients with upper tract urothelial carcinoma undergoing radical nephroureterectomy. Can J Urol 2012; 19: 6105-10. PubMed 
6. Favaretto RL, Shariat SF, Chade DC, et al. The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol 2010; 58: 574-80. PubMed 
7. Kreftregisteret. Cancer in Norway 2018. Oslo: Kreftregisteret, 2019. www.kreftregisteret.no